PMID- 15185343
OWN - NLM
STAT- MEDLINE
DCOM- 20040720
LR  - 20160303
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 111
IP  - 1
DP  - 2004 Aug 10
TI  - Altered mode of allelic replication accompanied by aneuploidy in peripheral blood 
      lymphocytes of prostate cancer patients.
PG  - 60-6
AB  - Replication timing of the genetic material is a highly programmed process 
      correlated with expression, stability and methylation capacity. An important 
      aspect of that timing is the temporal order of allelic replication: a synchronous 
      mode for biallelically expressed genes and an asynchronous for monoallelically 
      expressed genes. Previous studies showed that malignancy is associated with 
      changes in the inherent mode of allelic replication, and even normal cells of 
      cancer patients display alterations in the replication of various genes. Using 
      fluorescence in situ hybridization (FISH), we checked whether allelic-replication 
      mode differentiates cancer patients from healthy individuals. We focused on 
      prostate cancer (CAP), the most common diagnosed cancer and the second leading 
      cause of cancer death in men over 50 years old. Five nonrelated genes and a 
      nontranscribed DNA sequence associated with chromosomal segregation were used in 
      our study. All 6 tested loci displayed in peripheral blood lymphocytes stimulated 
      with phytohemagglutinin (PHA) of CAP patients loss of their inherent temporal 
      order of allelic replication, coupled with aneuploidy, the outcome of chromosome 
      malsegregation. The replication-timing modification is a reversible epigenetic 
      alteration, evidenced by our ability to resurrect the normal pattern in all 6 
      tested loci by introducing an inhibitor of methyl transferase. On the other hand, 
      the methylation-blocking agent failed to obliterate aneuploidy. The replication 
      alteration accompanied by aneuploidy, detected in peripheral blood cells, 
      distinguishes between CAP patients and individuals with benign prostate 
      hyperplasia (BPH; a common disorder in elderly men) better than the routinely 
      used blood marker, the prostate-specific antigen (PSA).
CI  - Copyright 2004 Wiley-Liss, Inc.
FAU - Dotan, Zohar A
AU  - Dotan ZA
AD  - Department of Human Genetics and Molecular Medicine, Sackler School of Medicine, 
      Tel Aviv University, Tel Aviv, Israel.
FAU - Dotan, Aviva
AU  - Dotan A
FAU - Ramon, Jacob
AU  - Ramon J
FAU - Avivi, Lydia
AU  - Avivi L
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Alleles
MH  - *Aneuploidy
MH  - Cell Cycle
MH  - *DNA Replication
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - *Lymphocytes
MH  - Male
MH  - Middle Aged
MH  - Prostatic Hyperplasia/genetics/physiopathology
MH  - Prostatic Neoplasms/*genetics/pathology
MH  - Time Factors
EDAT- 2004/06/09 05:00
MHDA- 2004/07/21 05:00
CRDT- 2004/06/09 05:00
PHST- 2004/06/09 05:00 [pubmed]
PHST- 2004/07/21 05:00 [medline]
PHST- 2004/06/09 05:00 [entrez]
AID - 10.1002/ijc.20237 [doi]
PST - ppublish
SO  - Int J Cancer. 2004 Aug 10;111(1):60-6. doi: 10.1002/ijc.20237.